Shanghai-based biopharmaceutical company Elpiscience Biopharmaceutical raised $100m in a Series B round to advance its immunotherapy drug candidates through pre-clinical and clinical stages. The funding round was led by Hyfinity Investments, an asset management firm. The other investors include Tencent Holdings, GTJA Investment Group, Dyee Capital, Oriza Holdings, Ming Bioventures, WisdoMont Asset Management and Parkway Global. Return backers included Lilly Asia Ventures, Hillhouse Capital and CDH Investments. "The participation of these top-notch investors greatly empowers us to continuously pursue the exciting journey of developing innovative drugs. We will stay committed to carefully exploring new scientific discovery towards finding effective therapies for cancer patients,” Darren Ji, Elpiscience Co-Founder and CEO.